MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas.
Rainer Kunstfeld
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Axel Hauschild
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono
David Zloty
Consultant or Advisory Role - Genentech
Honoraria - Presentation
Research Funding - MIKIE Vancouver Canada site
Gary Rogers
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Brigitte Dreno
Consultant or Advisory Role - Roche
Honoraria - Roche
Lada Mitchell
Employment or Leadership Position - Roche
Michal Starnawski
Employment or Leadership Position - Roche
Dirk Schadendorf
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche